参与P2X3受体拮抗剂gefapixant 2b期临床试验的慢性咳嗽患者的RT杂志文章SR电子T1表征欧洲呼吸杂志JO Eur Respir J FD欧洲呼吸学会SP PA612 DO 10.1183/1399300 .国会-2019。188bet官网地址PA612 VO 54 5 63 A1 McGarvey Lorcan A1史密斯,她A1出生,萨伦德A1 Morice, Alyn A1谢尔,曼德尔A1吴,Wen-Chi A1 Muccino,大卫年2019 UL //www.qdcxjkg.com/content/54/suppl_63/PA612.abstract AB背景:我们评估临床特点严重耐火材料/原因不明的慢性咳嗽患者(RCC / UCC)。方法:碾压混凝土/ UCC科目(咳嗽持续时间≥1年,严重血管> 40毫米)随机安慰剂或gefapixant(7.5毫克、20毫克或50毫克)在12周的双盲平行小组研究(NCT02612610)在RCC(在治疗慢性咳嗽未解决的基本条件)和UCC(潜在条件无法确定)科目(胸部吉布森PG。2016。149年:27-44)。基线时记录既往用药、病史和特征。结果:253名受试者(76%为女性，平均年龄60岁，30%为吸烟者)，平均咳嗽时间为14.2(11.1)年。大多数受试者被诊断为肾细胞癌;次要诊断包括胃食管反流病(GERD)(56.3%)、哮喘(29.8%)、变应性鼻炎(29.4%)和上呼吸道咳嗽综合征(12.3%)。最常见的早期治疗包括类固醇(21.4%)、抗组胺药(15.4%)、胃酸减少药(15.1%)、支气管扩张药(14.4%)和止咳药(阿片类药物[8.3%]或苯甲硝酸盐[9.1%])。最常见的基线病史项目，以前被描述为与咳嗽相关的并发症(Irwin RS Chest 2006)。 129 (1): 55S-58S) included headache (15.1%), hiatus hernia (12.7%), stress urinary incontinence (4.8%), bronchitis (4.4%), and urinary incontinence (2.8%).Conclusions: Large proportions of chronic cough patients in this trial were diagnosed with GERD, asthma, or allergic rhinitis. Despite receiving treatment for these conditions, chronic cough for these subjects had persisted for over a decade.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA612.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).